Editas Medicine Inc. [NASDAQ: EDIT] closed the trading session at $54.51 on 08/05/21. The day’s price range saw the stock hit a low of $47.49, while the highest price level was $55.00. The company report on August 4, 2021 that Editas Medicine Announces Second Quarter 2021 Results and Business Updates.
Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10.
EDIT-101 initial clinical data planned for September 2021.
The stocks have a year to date performance of -22.25 percent and weekly performance of 30.10 percent. The stock has been moved at -13.72 percent over the last six months. The stock has performed 19.28 percent around the most recent 30 days and changed 58.74 percent over the most recent 3-months.
If compared to the average trading volume of 1.67M shares, EDIT reached to a volume of 4874049 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Editas Medicine Inc. [EDIT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EDIT shares is $44.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EDIT stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for Editas Medicine Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 05, 2021. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on June 04, 2021, representing the official price target for Editas Medicine Inc. stock. Previously, the target price had yet another raise to $40, while RBC Capital Mkts analysts kept a Sector Perform rating on EDIT stock.
The Average True Range (ATR) for Editas Medicine Inc. is set at 3.92, with the Price to Sales ratio for EDIT stock in the period of the last 12 months amounting to 40.51. The Price to Book ratio for the last quarter was 5.64, with the Price to Cash per share for the same quarter was set at 9.20.
EDIT stock trade performance evaluation
Editas Medicine Inc. [EDIT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.10. With this latest performance, EDIT shares gained by 19.28% in over the last four-week period, additionally sinking by -13.72% over the last 6 months – not to mention a rise of 67.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EDIT stock in for the last two-week period is set at 72.16, with the RSI for the last a single of trading hit 80.24, and the three-weeks RSI is set at 67.32 for Editas Medicine Inc. [EDIT]. The present Moving Average for the last 50 days of trading for this stock 41.29, while it was recorded at 45.21 for the last single week of trading, and 45.74 for the last 200 days.
Editas Medicine Inc. [EDIT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Editas Medicine Inc. [EDIT] shares currently have an operating margin of -148.61. Editas Medicine Inc.’s Net Margin is presently recorded at -127.82.
Return on Total Capital for EDIT is now -37.92, given the latest momentum, and Return on Invested Capital for the company is -33.20. Return on Equity for this stock declined to -35.36, with Return on Assets sitting at -21.45. When it comes to the capital structure of this company, Editas Medicine Inc. [EDIT] has a Total Debt to Total Equity ratio set at 6.64. Additionally, EDIT Total Debt to Total Capital is recorded at 6.23, with Total Debt to Total Assets ending up at 4.56. Long-Term Debt to Equity for the company is recorded at 4.91, with the Long-Term Debt to Total Capital now at 4.60.
Reflecting on the efficiency of the workforce at the company, Editas Medicine Inc. [EDIT] managed to generate an average of -$493,515 per employee. Receivables Turnover for the company is 28.06 with a Total Asset Turnover recorded at a value of 0.17.Editas Medicine Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.90 and a Current Ratio set at 9.90.
Editas Medicine Inc. [EDIT]: Insider Ownership positions
There are presently around $2,849 million, or 77.30% of EDIT stock, in the hands of institutional investors. The top three institutional holders of EDIT stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 7,180,055, which is approximately -17.96% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 6,347,754 shares of the stock with an approximate value of $346.02 million in EDIT stocks shares; and BLACKROCK INC., currently with $312.74 million in EDIT stock with ownership of nearly 8.142% of the company’s market capitalization.
Positions in Editas Medicine Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 178 institutional holders increased their position in Editas Medicine Inc. [NASDAQ:EDIT] by around 7,887,327 shares. Additionally, 119 investors decreased positions by around 6,200,745 shares, while 62 investors held positions by with 38,183,513 shares. The mentioned changes placed institutional holdings at 52,271,585 shares, according to the latest SEC report filing. EDIT stock had 61 new institutional investments in for a total of 2,232,201 shares, while 54 institutional investors sold positions of 1,502,840 shares during the same period.